Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 754 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July June 25, 2025 Cancer Patients Get Free, Beautiful Henna Crowns From Local Artist March 17, 2020 Twins Born 15 Minutes Apart Have Birthdays In Different Years January 9, 2022 Home Is Where the Heart Is November 8, 2019 Load more HOT NEWS Disparities in Cancer Care Between Citizens and Refugees in Lebanon Glioblastoma Study Highlights Sex Differences in Brain Cancer Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected...
